ACT Brief: Organizational Shifts in Trial Design, Amyloid Antibody Evidence Review, and Compounding's Role in Care Continuity

In today's ACT Brief, we explore organizational factors behind CRL decisions, methodological concerns with pooling amyloid antibody trial data, and how compounding addresses care gaps when commercial options fall short.